Ocular Therapeutix (OCUL) announced that more than 300 patients have been randomized in the SOL-1 Phase 3 trial for AXPAXLI, and the trial is expected to close randomization this week. This is the first registrational clinical trial of AXPAXLI in wet age-related macular degeneration, which remains on track to report topline data in the fourth quarter of 2025.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCUL: